Cryptic Terran Licences Advanced CNS Assets From Sanofi
Deal Value Under Wraps
Executive Summary
The US biotech has nabbed a couple of Sanofi’s Phase III CNS candidates, its third deal of the year aimed at transforming the neuropsychiatry market.
You may also be interested in...
Deal Watch: Dragonfly Adds Gilead To Its List Of Big-Name Partners
AbbVie inks collaboration and option deal focused on targeted protein degradation with Plexium. Cend and Calabrius merge in an all-stock transaction.
Dupixent Drives Sanofi Growth Again Amid Pipeline Renewal
The major’s atopic dermatitis blockbuster made more than €1.6bn this quarter, but the firm’s R&D costs are rising as it attempts to add some fresh blood to its stagnating pipeline.
Sanofi Bets Big On IgM ‘Super Antibodies’ In Potential $6bn Cancer and Immunology Deal
Looking to catch up with leaders in in the field of next-generation antibodies, Sanofi has struck a deal with IGM Biosciences for three cancer and three auto-immune/inflammation IgM candidates that hold the promise of greater efficacy.